Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
Abroad (travel likely)RecruitingPHASE1, PHASE2
Conditions
Recurrent B-Cell Non-Hodgkin Lymphoma · Refractory B-cell Non-Hodgkin Lymphoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Contact: Principal Investigator (Yago Nieto, MD,PHD)
Study leads
Yago Nieto, MD,PHD
Principal Investigator
M.D. Anderson Cancer Center